The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 19, 2024

Filed:

Apr. 23, 2021
Applicant:

Genecraft Inc., Cheongju-si, KR;

Inventors:

Suk Chul Bae, Cheongju-si, KR;

Jung Won Lee, Daejeon, KR;

You Soub Lee, Cheongju-si, KR;

Assignee:

GeneCraft Inc., Cheongju-si, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 31/436 (2006.01); A61K 31/519 (2006.01); A61K 47/46 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/17 (2013.01); A61K 31/436 (2013.01); A61K 31/519 (2013.01); A61K 38/1709 (2013.01); A61K 47/46 (2013.01); A61P 35/00 (2018.01); C07K 14/4702 (2013.01); C12N 7/00 (2013.01); C12N 2750/14143 (2013.01);
Abstract

In the present invention, it was confirmed that the modified protein in which the 356serine of Runx3 is substituted with alanine has an increased activity of maintaining the complex with Brd2 by more than 10 times compared to the wild-type Runx3, and the apoptosis effect is improved in various cancer cell lines compared to the wild-type Runx3. Therefore, the modified protein in which the 356serine of Runx3 is substituted with an amino acid that cannot be phosphorylated by a kinase of the present invention, the polynucleotide coding thereof, the vector carrying the polynucleotide, or the virus or cell transformed with the vector can be used as a therapeutic agent for various cancers.


Find Patent Forward Citations

Loading…